With a pivotal trial slated to start next quarter for lead immunotherapy candidate AGS-003 in metastatic renal cell carcinoma, Argos Therapeutics Inc. decided to take a chance on the initial public offering (IPO) market, which, after a couple of dry months, seems to be picking back up again.